Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Clinical Pharmaceutical Laboratory of Traditional Chinese Medicine, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
Pathol Oncol Res. 2021 Apr 9;27:529240. doi: 10.3389/pore.2021.529240. eCollection 2021.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. The nuclear factor of activated T cells (NFAT) family is implicated in tumorigenesis and progression in various types of cancer. However, little is known about their expression patterns, distinct prognostic values, and potential regulatory networks in NSCLC. In this study, we comprehensively analyzed the distinct expression and prognostic value of in NSCLC through various large databases, including the Oncomine, UCSC Xena Browser, UALCAN databases, Kaplan-Meier Plotter, cBioPortal, and Enrichr. In lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), mRNA expression levels were significantly decreased and mRNA expression level was significantly increased. The cBioPortal database analysis showed that the mRNA dysregulation was one of the single most important factors for alteration in LUAD and LUSC and that both LUAD and LUSC cases with the alterations in the mRNA expression of had significantly better overall survival (OS). High expression levels of were significantly associated with better OS in LUAD, whereas high expression led to a worse OS. Overexpression of NFAT1/2 predicted better OS in LUSC, whereas high expression led to a worse OS. The networks for NFATs and the 50 most frequently altered neighbor genes in LUAD and LUSC were also constructed. NFATs and genes significantly associated with mRNA expression in LUAD and LUSC were significantly enriched in the cGMP-dependent protein kinase and Wnt signaling pathways. These results showed that the NFAT family members displayed varying degrees of abnormal expressions, suggesting that NFATs may be therapeutic targets for patients with NSCLC. Aberrant expression of NFATs was found to be associated with OS in the patients with NSCLC; among NFATs, NFAT3/4 may be new biomarkers for the prognosis of LUAD. However, further studies are required to validate our findings.
非小细胞肺癌(NSCLC)是全球癌症相关死亡的主要原因。核因子活化 T 细胞(NFAT)家族参与多种类型癌症的发生和进展。然而,关于它们在 NSCLC 中的表达模式、不同的预后价值和潜在的调控网络知之甚少。在这项研究中,我们通过 Oncomine、UCSC Xena Browser、UALCAN 数据库、Kaplan-Meier Plotter、cBioPortal 和 Enrichr 等各种大型数据库,全面分析了 NFAT 家族在 NSCLC 中的不同表达和预后价值。在肺腺癌(LUAD)和肺鳞状细胞癌(LUSC)中,NFAT1、NFAT2 和 NFAT5 的 mRNA 表达水平显著降低,而 NFAT3/4 的 mRNA 表达水平显著升高。cBioPortal 数据库分析表明,mRNA 失调是 LUAD 和 LUSC 中 NFAT 改变的最重要因素之一,且 NFAT 改变的 LUAD 和 LUSC 病例的总生存期(OS)显著改善。NFAT1/2 的高表达与 LUAD 的 OS 显著相关,而 表达升高则导致 OS 较差。LUSC 中 NFAT1/2 的过表达预测 OS 较好,而 表达升高则导致 OS 较差。还构建了 LUAD 和 LUSC 中 NFATs 和最常改变的 50 个相邻基因的网络。与 LUAD 和 LUSC 中 表达相关的 NFATs 和基因在 cGMP 依赖性蛋白激酶和 Wnt 信号通路中显著富集。这些结果表明 NFAT 家族成员显示出不同程度的异常表达,提示 NFAT 可能成为 NSCLC 患者的治疗靶点。NFAT 的异常表达与 NSCLC 患者的 OS 相关;在 NFAT 中,NFAT3/4 可能是 LUAD 预后的新生物标志物。然而,需要进一步的研究来验证我们的发现。